Leerink Lifts PT on Ultragenyx Pharma (RARE) to $94 Amid Solid KRN23 Data in XLH

September 19, 2016 3:48 PM EDT Send to a Friend
Leerink boosts its price target on Ultragenyx Pharma (Nasdaq: RARE) from $85 to $94 after the company announced positive interim ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login